ArticlePharmaceutical research2011
Controlled release of IGF-1 and HGF from a biodegradable polyurethane scaffold.
Article in Pharmaceutical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Design of Hybrid Polymer Nanofiber/Collagen Patches Releasing IGF and HGF to Promote Cardiac Regeneration.Pharmaceutics · 2022Article
- Sustained Release of Insulin-Like Growth Factor-1 fromInternational journal of molecular sciences · 2021Article
- Nitro-Oleic Acid (NOTissue engineering. Part A · 2018Article
- Tunable Keratin Hydrogels for Controlled Erosion and Growth Factor Delivery.Biomacromolecules · 2016Article
- Antifibrotic therapies to control cardiac fibrosis.Biomaterials research · 2016Review
- Biomimetic scaffolds for regeneration of volumetric muscle loss in skeletal muscle injuries.Acta biomaterialia · 2015Review
- Naturally derived and synthetic scaffolds for skeletal muscle reconstruction.Advanced drug delivery reviews · 2015Review
- Predicting in vivo responses to biomaterials via combined in vitro and in silico analysis.Tissue engineering. Part C, Methods · 2015Article
- Electrospun biodegradable elastic polyurethane scaffolds with dipyridamole release for small diameter vascular grafts.Acta biomaterialia · 2014Article
- Biomimetic scaffold combined with electrical stimulation and growth factor promotes tissue engineered cardiac development.Experimental cell research · 2014Article
- Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo.Advanced materials (Deerfield Beach, Fla.) · 2014Article
- Biodegradable elastic patch plasty ameliorates left ventricular adverse remodeling after ischemia-reperfusion injury: a preclinical study of a porous polyurethane material in a porcine model.The Journal of thoracic and cardiovascular surgery · 2013Article
- The pharmacology of regenerative medicine.Pharmacological reviews · 2013Review
- Synthesis, characterization, and paclitaxel release from a biodegradable, elastomeric, poly(ester urethane)urea bearing phosphorylcholine groups for reduced thrombogenicity.Biomacromolecules · 2012Article
- Sustained local delivery of siRNA from an injectable scaffold.Biomaterials · 2012Article
- Biodegradable polyurethane ureas with variable polyester or polycarbonate soft segments: effects of crystallinity, molecular weight, and composition on mechanical properties.Biomacromolecules · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeBiodegradable elastomers, which can possess favorable mechanical properties and degradation rates for soft tissue engineering applications, are more recently being explored as depots for biomolecule delivery. The objective of this study was to synthesize and process biodegradable, elastomeric poly(ester urethane)urea (PEUU) scaffolds and to characterize their ability to incorporate and release bioactive insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF).
methodsPorous PEUU scaffolds made from either 5 or 8 wt% PEUU were prepared with direct growth-factor incorporation. Long-term in vitro IGF-1 release kinetics were investigated in saline or saline with 100 units/ml lipase to simulate in vivo degradation. Cellular assays were used to confirm released IGF-1 and HGF bioactivity.
resultsIGF-1 release into saline occurred in a complex multi-phasic manner for up to 440 days. Scaffolds generated from 5 wt% PEUU delivered protein faster than 8 wt% scaffolds. Lipase-accelerated scaffold degradation led to delivery of >90% protein over 9 weeks for both polymer concentrations. IGF-1 and HGF bioactivity in the first 3 weeks was confirmed.
conclusionsThe capacity of a biodegradable elastomeric scaffold to provide long-term growth-factor delivery was demonstrated. Such a system might provide functional benefit in cardiovascular and other soft tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.